SCHEMBL2790691

SCHEMBL2790691

N=C(N)NCCC(=O)N(CCc1c[nH]c2ccccc12)C(C(=O)Nc1ccccc1)c1ccccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.45
KMT2A Q03164 8/20 0.45
MAPT P10636 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GOT1 P17174 5/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
POLB P06746 1/20 0.42
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
HDAC8 Q9BY41 1/20 0.40
MC5R P33032 1/20 0.39
MC3R P41968 1/20 0.39
LMNA P02545 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2788832 0.93 MEN1 (0.41) MEN1KMT2AMAPTSMN1; SMN2GOT1
SCHEMBL9943290 0.92 ACHE (0.40) MEN1KMT2AMAPTSMN1; SMN2GOT1
SCHEMBL2787930 0.91 MEN1 (0.45) MEN1KMT2AMAPTSMN1; SMN2NPC1
SCHEMBL2787736 0.91 MEN1 (0.45) MEN1KMT2AMAPTSMN1; SMN2GOT1
SCHEMBL2788365 0.90 GOT1 (0.49) MEN1KMT2AMAPTSMN1; SMN2GOT1
SCHEMBL9943439 0.89 MC5R (0.47) MEN1KMT2AMAPTSMN1; SMN2GOT1
SCHEMBL2790038 0.89 MEN1 (0.51) MEN1KMT2AMAPTSMN1; SMN2POLB
SCHEMBL2787635 0.89 MAPT (0.47) MEN1KMT2AMAPTSMN1; SMN2CDK4
SCHEMBL2789684 0.87 GOT1 (0.52) MEN1KMT2AMAPTSMN1; SMN2GOT1
SCHEMBL2787992 0.86 GOT1 (0.49) MEN1KMT2AMAPTSMN1; SMN2GOT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227502-B2 Amides acting on the adenosine receptors ANAMAR AB (SE) 2012-07-24 US claimed
EP-2099815-B1 NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS ANAMAR AB (SE) 2012-06-20 EP claimed
EP-2099815-A2 NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS Acure Pharma AB (SE) 2009-09-16 EP claimed
WO-2008058679-A2 NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS ACURE PHARMA AB (SE) 2008-05-22 WO claimed
US-8227502-B2 Amides acting on the adenosine receptors ANAMAR AB (SE) 2012-07-24 US disclosed
EP-2099815-B1 NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS ANAMAR AB (SE) 2012-06-20 EP disclosed
US-20100098629-A1 Novel Amides Acting on the Adenosine Receptors ACURE PHARMA AB (SE) 2010-04-22 US disclosed
EP-2099815-A2 NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS Acure Pharma AB (SE) 2009-09-16 EP disclosed
WO-2008058679-A2 NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS ACURE PHARMA AB (SE) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098629-A1 Novel Amides Acting on the Adenosine Receptors ADORA1, ADORA3, ADORA2B MEN1 4664/4885KMT2A 3804/4885MAPT 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.